LAKESHORE BIOPHARMA CO LTD (LSB) Fundamental Analysis & Valuation

NASDAQ:LSB • KYG9845F2080

Current stock price

0.627 USD
-0.16 (-20.68%)
At close:
0.5399 USD
-0.09 (-13.89%)
After Hours:

This LSB fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

2

1. LSB Profitability Analysis

1.1 Basic Checks

  • In the past year LSB has reported negative net income.
  • LSB had a negative operating cash flow in the past year.
  • LSB had negative earnings in each of the past 5 years.
  • LSB had a negative operating cash flow in each of the past 5 years.
LSB Yearly Net Income VS EBIT VS OCF VS FCFLSB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 2024 2025 -100M -200M -300M -400M

1.2 Ratios

  • LSB has a Return On Assets of -7.31%. This is amongst the best in the industry. LSB outperforms 86.30% of its industry peers.
  • LSB has a Return On Equity of -20.01%. This is amongst the best in the industry. LSB outperforms 84.81% of its industry peers.
Industry RankSector Rank
ROA -7.31%
ROE -20.01%
ROIC N/A
ROA(3y)-17.48%
ROA(5y)-10.54%
ROE(3y)-44.33%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
LSB Yearly ROA, ROE, ROICLSB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 2024 2025 -20 -40 -60

1.3 Margins

  • Looking at the Gross Margin, with a value of 82.47%, LSB belongs to the top of the industry, outperforming 85.74% of the companies in the same industry.
  • The Profit Margin and Operating Margin are not available for LSB so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 82.48%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
LSB Yearly Profit, Operating, Gross MarginsLSB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 2024 2025 0 50 -50

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

1

2. LSB Health Analysis

2.1 Basic Checks

  • LSB does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for LSB has been increased compared to 1 year ago.
  • LSB has a worse debt/assets ratio than last year.
LSB Yearly Shares OutstandingLSB Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2024 2025 5M 10M 15M 20M 25M
LSB Yearly Total Debt VS Total AssetsLSB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 2024 2025 500M 1B 1.5B

2.2 Solvency

  • LSB has an Altman-Z score of -1.99. This is a bad value and indicates that LSB is not financially healthy and even has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of -1.99, LSB is in line with its industry, outperforming 52.04% of the companies in the same industry.
  • LSB has a Debt/Equity ratio of 0.05. This is a healthy value indicating a solid balance between debt and equity.
  • The Debt to Equity ratio of LSB (0.05) is worse than 60.56% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.05
Debt/FCF N/A
Altman-Z -1.99
ROIC/WACCN/A
WACC5.01%
LSB Yearly LT Debt VS Equity VS FCFLSB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 2024 2025 0 200M -200M 400M 600M

2.3 Liquidity

  • A Current Ratio of 1.02 indicates that LSB should not have too much problems paying its short term obligations.
  • Looking at the Current ratio, with a value of 1.02, LSB is doing worse than 87.22% of the companies in the same industry.
  • A Quick Ratio of 0.75 indicates that LSB may have some problems paying its short term obligations.
  • The Quick ratio of LSB (0.75) is worse than 89.44% of its industry peers.
Industry RankSector Rank
Current Ratio 1.02
Quick Ratio 0.75
LSB Yearly Current Assets VS Current LiabilitesLSB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2024 2025 200M 400M 600M 800M 1B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. LSB Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 87.13% over the past year.
  • The Revenue has been growing slightly by 7.24% in the past year.
EPS 1Y (TTM)87.13%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%70.82%
Revenue 1Y (TTM)7.24%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%79.55%

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • Based on estimates for the next years, LSB will show a very negative growth in Revenue. The Revenue will decrease by -19.01% on average per year.
EPS Next Y105.67%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year75.61%
Revenue Next 2Y-43.54%
Revenue Next 3Y-29.5%
Revenue Next 5Y-19.01%

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
LSB Yearly Revenue VS EstimatesLSB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2024 2025 2026 2027 2028 2029 500M 1B
LSB Yearly EPS VS EstimatesLSB Yearly EPS VS EstimatesYearly EPS VS Estimates 2024 2025 2026 0 -10 -20 -30

More info and screens

Find the best growth stocksShow best growing peers

4

4. LSB Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for LSB. In the last year negative earnings were reported.
  • A Price/Forward Earnings ratio of 4.39 indicates a rather cheap valuation of LSB.
  • Based on the Price/Forward Earnings ratio, LSB is valued cheaply inside the industry as 99.07% of the companies are valued more expensively.
  • The average S&P500 Price/Forward Earnings ratio is at 23.84. LSB is valued rather cheaply when compared to this.
Industry RankSector Rank
PE N/A
Fwd PE 4.39
LSB Price Earnings VS Forward Price EarningsLSB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
LSB Per share dataLSB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 1.5 2

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. LSB Dividend Analysis

5.1 Amount

  • LSB does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

LSB Fundamentals: All Metrics, Ratios and Statistics

LAKESHORE BIOPHARMA CO LTD

NASDAQ:LSB (9/19/2025, 8:26:53 PM)

After market: 0.5399 -0.09 (-13.89%)

0.627

-0.16 (-20.68%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)07-31
Earnings (Next)12-15
Inst Owners0.66%
Inst Owner ChangeN/A
Ins Owners12.67%
Ins Owner ChangeN/A
Market Cap25.84M
Revenue(TTM)614.96M
Net Income(TTM)-99.98M
Analysts80
Price Target31.62 (4943.06%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 4.39
P/S 0.3
P/FCF N/A
P/OCF N/A
P/B 0.37
P/tB 0.43
EV/EBITDA N/A
EPS(TTM)-0.73
EYN/A
EPS(NY)0.14
Fwd EY22.79%
FCF(TTM)-0.47
FCFYN/A
OCF(TTM)-0.41
OCFYN/A
SpS2.09
BVpS1.7
TBVpS1.45
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -7.31%
ROE -20.01%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 82.48%
FCFM N/A
ROA(3y)-17.48%
ROA(5y)-10.54%
ROE(3y)-44.33%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.45
Health
Industry RankSector Rank
Debt/Equity 0.05
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 48.73%
Cap/Sales 2.9%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.02
Quick Ratio 0.75
Altman-Z -1.99
F-Score4
WACC5.01%
ROIC/WACCN/A
Cap/Depr(3y)103.04%
Cap/Depr(5y)328.9%
Cap/Sales(3y)6.31%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)87.13%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%70.82%
EPS Next Y105.67%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)7.24%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%79.55%
Revenue Next Year75.61%
Revenue Next 2Y-43.54%
Revenue Next 3Y-29.5%
Revenue Next 5Y-19.01%
EBIT growth 1Y82.81%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year162.66%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y59.1%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y59.02%
OCF growth 3YN/A
OCF growth 5YN/A

LAKESHORE BIOPHARMA CO LTD / LSB Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for LAKESHORE BIOPHARMA CO LTD?

ChartMill assigns a fundamental rating of 2 / 10 to LSB.


Can you provide the valuation status for LAKESHORE BIOPHARMA CO LTD?

ChartMill assigns a valuation rating of 4 / 10 to LAKESHORE BIOPHARMA CO LTD (LSB). This can be considered as Fairly Valued.


Can you provide the profitability details for LAKESHORE BIOPHARMA CO LTD?

LAKESHORE BIOPHARMA CO LTD (LSB) has a profitability rating of 2 / 10.


What is the earnings growth outlook for LAKESHORE BIOPHARMA CO LTD?

The Earnings per Share (EPS) of LAKESHORE BIOPHARMA CO LTD (LSB) is expected to grow by 105.67% in the next year.